Skip to content
TGMCharts
CompoundersResearchCompare
TGM Charts

Your trusted source for comprehensive financial data, stock research, and market analysis.

Quick Links

  • Login
  • Sign up
  • Stock Screener
  • Watchlist

Explore

  • Compounders
  • Compare Stocks
  • Stock Lists
  • Research
  • Highest Dividend Yield
  • Lowest P/E Ratio
  • Dividend Aristocrats

Company

  • About Us
  • Contact
  • Help Center

Join Our Community

Connect with fellow investors, share ideas, and get product updates in our Discord community.

Join our Discord

Important disclaimer

TGMCharts is a financial-data and research tool, not a broker-dealer, investment adviser, or financial planner, and nothing on this site is a recommendation or solicitation to buy, sell, or hold any security. Everything we publish is for general informational and educational purposes only and is not personalized investment, legal, or tax advice. Figures are sourced from third-party providers and our own calculations; while we work hard to keep them accurate and current, we do not warrant that any data, metric, chart, or analysis is complete, error-free, or up to date, and prices are not real-time. Past performance does not predict future results, and any decision you make using this site is your own responsibility. To the fullest extent permitted by law, TGM Ventures, Inc. and TGMCharts are not liable for any loss or damage arising from use of, or reliance on, anything on this site. Company names and logos are the property of their respective owners and appear for identification and editorial purposes only.

© 2026 TGM Charts. All rights reserved.

TermsPrivacyDisclaimer
Vertex Pharmaceuticals Incorporated (VRTX) Compounder Charts | TGMCharts
Home/Compounders/VRTX

Vertex Pharmaceuticals Incorporated (VRTX) compounder charts

Annual EBITDA and quarterly year-over-year growth against the 30% line over the last 3 years — compounder charts by TGMCharts.

Metric

RevenueEPSOperating cash flowEBITDAFree cash flow

Growth bar

30%+20%+15%+

Window

3Y5Y10Y

EBITDA · 3YDoes not currently clear the 15%+, 20%+, or 30%+ EBITDA bars over 3Y.

Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
Score
25/100
3Y CAGR
3.7%
Median YoY
4.2%
YoY volatility
σ 32.5pp· choppy
Quarters ≥ 30%
2 of 10
Negative quarters
4
Valuation vs own 3Y history
EV/EBITDA 26.4x · 3Y median 24.9x · 81st percentile
Why this rank
  • Quarters at or above 30%: 2 of 10 → 8 of 40 pts
  • Steadiness (typical swing 32.5pp) → 1.8 of 25 pts
  • Pace (median 4.2% YoY) → 0 of 20 pts
  • Latest quarter (76% YoY) → 15 of 15 pts
  • Score: 25 of 100

Annual ebitda · last 11 fiscal years

$-1.00B$0.00$1.00B$2.00B$3.00B$4.00B$5.00B201520172019202120232025
tgmcharts.com

Quarterly YoY ebitda growth vs the 30% line · 3Y

-50%-25%0%25%50%75%100%30%202420252026
tgmcharts.com

EV/EBITDA multiple vs its 3Y median · context only

0x250x500x750x1000x3Y median 24.9x20182020202220242026
tgmcharts.com

Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →